alendronate has been researched along with Vascular Calcification in 5 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Vascular Calcification: Deposition of calcium into the blood vessel structures. Excessive calcification of the vessels are associated with ATHEROSCLEROTIC PLAQUES formation particularly after MYOCARDIAL INFARCTION (see MONCKEBERG MEDIAL CALCIFIC SCLEROSIS) and chronic kidney diseases which in turn increase VASCULAR STIFFNESS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Alendronate, a bisphosphonate, is widely used in the treatment of osteoporosis and may be used to inhibit vascular calcification." | 3.79 | Effects of alendronate on the Notch1‑RBP‑Jκ signaling pathway in the osteogenic differentiation and mineralization of vascular smooth muscle cells. ( Fang, X; Guan, S; Xin, H; Zhou, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hildebrand, S | 1 |
| Cunningham, J | 1 |
| Pawade, TA | 1 |
| Doris, MK | 1 |
| Bing, R | 1 |
| White, AC | 1 |
| Forsyth, L | 1 |
| Evans, E | 1 |
| Graham, C | 1 |
| Williams, MC | 1 |
| van Beek, EJR | 1 |
| Fletcher, A | 1 |
| Adamson, PD | 1 |
| Andrews, JPM | 1 |
| Cartlidge, TRG | 1 |
| Jenkins, WSA | 1 |
| Syed, M | 1 |
| Fujisawa, T | 1 |
| Lucatelli, C | 1 |
| Fraser, W | 1 |
| Ralston, SH | 1 |
| Boon, N | 1 |
| Prendergast, B | 1 |
| Newby, DE | 1 |
| Dweck, MR | 1 |
| Zhou, S | 1 |
| Fang, X | 1 |
| Xin, H | 1 |
| Guan, S | 1 |
| Li, Q | 1 |
| Sundberg, JP | 1 |
| Levine, MA | 1 |
| Terry, SF | 1 |
| Uitto, J | 1 |
| Moore, SN | 1 |
| Tanner, SB | 1 |
| Schoenecker, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| SALTIRE II: Bisphosphonates and RANKL Inhibition in Aortic Stenosis[NCT02132026] | Phase 2 | 152 participants (Actual) | Interventional | 2014-11-12 | Completed | ||
| Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)[NCT04660461] | Phase 4 | 20 participants (Anticipated) | Interventional | 2020-02-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for alendronate and Vascular Calcification
| Article | Year |
|---|---|
Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis: A Double-Blind Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Alendronate; Aortic Valve Stenosis; Bone Density Conservation Agents; Denos | 2021 |
4 other studies available for alendronate and Vascular Calcification
| Article | Year |
|---|---|
Is there a role for bisphosphonates in vascular calcification in chronic kidney disease?
Topics: Alendronate; Diphosphonates; Female; Humans; Ibandronic Acid; Renal Insufficiency, Chronic; Vascular | 2021 |
Effects of alendronate on the Notch1‑RBP‑Jκ signaling pathway in the osteogenic differentiation and mineralization of vascular smooth muscle cells.
Topics: Alendronate; Alkaline Phosphatase; Animals; Calcium; Cell Differentiation; Gene Expression Regulatio | 2013 |
The effects of bisphosphonates on ectopic soft tissue mineralization caused by mutations in the ABCC6 gene.
Topics: Alendronate; Animals; ATP-Binding Cassette Transporters; Bone Density Conservation Agents; Drug Eval | 2015 |
Bisphosphonates: from softening water to treating PXE.
Topics: Alendronate; Animals; ATP-Binding Cassette Transporters; Bone Density Conservation Agents; Etidronic | 2015 |